Please use this identifier to cite or link to this item:
Título : Melatonin and healthy aging
Autor : Cardinali, Daniel Pedro 
Fecha de publicación : 2021
Editorial : Elsevier
Cita : Cardinali, D.P. Melatonin and healthy aging [en línea]. En: Litwack, G. (eds.). Vitamins and Hormones. Elsevier, 2021 doi:10.1016/bs.vh.2020.12.004
Resumen : Abstract: Preservation of a robust circadian rhythmicity (particulsarly of the sleep/wake cycle), a proper nutrition and adequate physical exercise are key elements for healthy aging. Aging comes along with circadian alteration, e.g. a disrupted sleep and inflammation, that leads to metabolic disorders. In turn, sleep cycle disturbances cause numerous pathophysiological changes that accelerates the aging process. In the central nervous system, sleep disruption impairs several functions, among them, the clearance of waste molecules. The decrease of plasma melatonin, a molecule of unusual phylogenetic conservation present in all known aerobic organisms, plays a particular role as far as the endocrine sequels of aging. Every day, the late afternoon/nocturnal increase of melatonin synchronizes both the central circadian pacemaker located in the hypothalamic suprachiasmatic nuclei as well as myriads of peripheral cellular circadian clocks. This is called the “chronobiotic effect” of melatonin, the methoxyindole being the prototype of the endogenous family of chronobiotic agents. In addition, melatonin exerts a significant cytoprotective action by buffering free radicals and reversing inflammation via down regulation of proinflammatory cytokines, suppression of low degree inflammation and prevention of insulin resistance. Because of these properties melatonin has been advocated to be a potential therapeutic tool in COVID 19 pandemic. Melatonin administration to aged animals counteracts a significant number of senescence-related changes. In humans, melatonin is effective both as a chronobiotic and a cytoprotective agent to maintain a healthy aging. Circulating melatonin levels are consistently reduced in the metabolic syndrome, ischemic and non-ischemic cardiovascular diseases and neurodegenerative disorders like the Alzheimer's and Parkinson's diseases. The potential therapeutic value of melatonin has been suggested by a limited number of clinical trials generally employing melatonin in the 2–10 mg/day range. However, from animal studies the cytoprotective effects of melatonin need higher doses to become apparent (i.e. in the 100 mg/day range). Hence, controlled studies employing melatonin doses in this range are urgently needed.
ISBN : 978-0-323-85548-8
ISSN : 0083-6729
Disciplina: MEDICINA
DOI: 10.1016/bs.vh.2020.12.004
Derechos: Acceso abierto. 24 meses de embargo
Appears in Collections:Libros o partes de libro

Files in This Item:
File Description SizeFormat Existent users please Login
melatonin-healthy-aging.pdf389,34 kBAdobe PDF???    Request a copy
cover.gif15,52 kBGIFThumbnail
Show full item record

Page view(s)

checked on Dec 7, 2023


checked on Dec 7, 2023

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons